| Document |
Document Title |
|
WO/2022/073445A1 |
Provided is a fused ring diimide derivative having a chemical structure as represented by formula I. Further provided is a preparation method therefor. The fused ring diimide derivative has excellent anti-tumor activity, and the anti-pro...
|
|
WO/2022/063784A1 |
Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods fo...
|
|
WO/2022/067114A1 |
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disor...
|
|
WO/2022/053704A1 |
The present invention relates to novel candidates for treating viral infections such as HIV, Epstein Barr virus, HPV (Papillomavirus), SARS coronavirus, Ebola virus, Marburg virus, Zika, Herpes (HHV), Hepatitis B, Hepatitis C, Kaposi's s...
|
|
WO/2022/051596A1 |
The present disclosure relates to compounds of Formula (I') and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2022/040747A1 |
The present invention relates to compounds that have zinc and/or iron ionophore activity and their use in treating diseases that are modulated by reducing zinc and/or iron. In particular embodiments, the compounds are compounds of formul...
|
|
WO/2022/040002A1 |
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
|
|
WO/2022/022612A1 |
The invention relates to novel glutamine analogs shown as the formula I, a composition containing the glutamine analogs and the use thereof.
|
|
WO/2022/023572A2 |
Provided are a compound of Formula I or Formula IA, a composition comprising a compound of Formula I or Formula IA, uses of the compounds and compositions to modulate insect behaviour and methods for modulating insect behaviour. Also pro...
|
|
WO/2022/026500A1 |
Disclosed are compounds of Formula 1, all stereoisomers, N-oxides and salts thereof, wherein G is CONR5R6 or selected from and R1 through R18 Rf and G are as defined in the Disclosure. Also disclosed are compositions containing the compo...
|
|
WO/2022/026548A1 |
Disclosed herein are certain acetamido derivatives that are DNA Polymerase Theta (Ροlθ) inhibitors of Formula (I). Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by...
|
|
WO/2022/018679A1 |
The present disclosure discloses a compound of Formula (I) and its polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof and a process of preparation of comp...
|
|
WO/2022/013408A2 |
The present invention relates to cyclic cyanoenone derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R2, R3, R4 and m are as defined herein. The present invention also relates to pharmaceuti...
|
|
WO/2022/008784A1 |
Use of simple acyclic polyamines for the treatment of parasites of the family Trypanosomatidae. The present invention provides the use of certain simple acyclic polyamines of Formula (I), attached to heterocycles, for the treatment of le...
|
|
WO/2021/255607A1 |
The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use di...
|
|
WO/2021/233428A1 |
A nitrogen-containing saturated heterocyclic compound having the structure of formula (I) and a preparation method therefor, a pharmaceutical composition, and an application. The nitrogen-containing saturated heterocyclic compound is a s...
|
|
WO/2021/235392A1 |
The present invention relates to an anti-SARS-CoV-2 drug including, as an active ingredient, a compound represented by formula (I): [wherein R1 is C1-C8 alkyl or the like; and R2-R9 is hydrogen, halogen, hydroxyl, or Q-(C1-C8 alkyl) (Q i...
|
|
WO/2021/228216A1 |
The present invention relates to a compound of formula (I), and a stereisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, a pharmaceutical composition comprising the compound, a method...
|
|
WO/2021/226276A2 |
Provided are compounds of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, n, and Y1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a ph...
|
|
WO/2021/218755A1 |
The present invention relates to a compound (as represented by formula I) serving as an Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor, a pharmaceutical composition thereof, a preparation method therefor...
|
|
WO/2021/218752A1 |
Provided herein are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.
|
|
WO/2021/209689A1 |
A composition comprising a compound or a salt thereof is disclosed. A method for treating a plant curatively and/or preventively against at least one plant pathogenic virus and/or against sweet potato virus disease (SPVD), as well as use...
|
|
WO/2021/195183A1 |
The invention provides compounds that are inhibitors of the protein embryonic ectoderm development (EED), pharmaceutical compositions, their use in modulating the activity of EED, and their use in the treatment of medical disorders, such...
|
|
WO/2021/191062A1 |
The present invention provides a process for preparing (R)-6-(tert-butoxycarbonyl)-6- azaspiro[2.5]octane-5-carboxylic acid (SM1), said process comprising the step of: iv) converting a compound of formula (VII) into a compound of formula...
|
|
WO/2021/180081A1 |
Provided is a compound having the structure represented by formula (I), or a stereoisomer, N-oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof. Further provided are a pharmaceutical composition comprising th...
|
|
WO/2021/150700A1 |
A genus of N-substituted-3-tricyclyl piperidine derivatives is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, ex...
|
|
WO/2021/150806A1 |
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical...
|
|
WO/2021/150697A1 |
A genus of N-substituted-3-tricyclyl piperidine derivatives is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, ex...
|
|
WO/2021/143885A1 |
A fused tetracyclic compound and an application thereof in a medicine, and in particular, an application of the fused tetracyclic compound as a medicine for treating and/or preventing hepatitis B. Specifically, the invention relates to a...
|
|
WO/2021/142065A1 |
This disclosure provides a cridin-9-yl-amine, quinolin-9-yl-amine, 1- amino-9H-thioxanthene-9-one and benzo[b][l,5]naphthyridin-10- yl-amine derivatives and structurally related compounds for use as autophagy inhibitors for treating canc...
|
|
WO/2021/130257A1 |
The present invention relates to dihydro‐cyclopenta‐isoquinoline derivatives of formula (I): processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergi...
|
|
WO/2021/131697A1 |
A purpose of the present invention is to provide a metal complex useful for producing a luminescent element exhibiting an improved luminance life, and the other purpose is to provide a composition containing the metal complex and a lumin...
|
|
WO/2021/130260A1 |
The present invention relates to tetrahydrobenzo-isoquinoline sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as al...
|
|
WO/2021/130259A1 |
The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as ...
|
|
WO/2021/127429A1 |
The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating ca...
|
|
WO/2021/127071A1 |
The present invention relates to novel Bicyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, Z, R1 R5, R6, and R7 are as defined herein. The present invention also relates to compos...
|
|
WO/2021/122538A1 |
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2021/107030A1 |
This compound is represented by formula (12X). In formula (12X), Py1 and Py2 each independently represent a substituted or unsubstituted 1-pyrenyl group, and L1 and L2 each independently represent a substituted or unsubstituted phenylene...
|
|
WO/2021/103060A1 |
Disclosed are a hole transport material, a preparation method therefor, and an organic light emitting device, the hole transport material comprising a compound having a chemical structure represented by formula I, Z comprising a carbon a...
|
|
WO/2021/103728A1 |
An organic compound and an organic electroluminescent device using the compound used for the field of organic electroluminescence. The organic compound is as shown in structural formula I, wherein Ar1 to Ar 4 are independently selected f...
|
|
WO/2021/098809A1 |
Disclosed are a bicyclic compound used as a non-steroidal selective androgen receptor modulator and the use thereof in the preparation of a drug for treating related diseases which are mediated by an androgen receptor. Specifically, the ...
|
|
WO/2021/097139A1 |
Disclosed herein are methods for preparing tertiary alcohols from an optionally substituted phenyl ketone or an optionally substituted pyridinyl ketone that includes the use of a chiral ligand and boron trifluoride diethyl etherate. Tert...
|
|
WO/2021/090850A1 |
The present invention relates to a compound represented by general formula (1) or a salt thereof. In general formula (1), R1, R2, R3 and R4 are each independently a hydrogen atom, an optionally substituted straight-chain or a branched ...
|
|
WO/2021/084472A1 |
Electrochemiluminescence (ECL) lable molecules, detection reagents labled with the ECL label molecules, and methods of using the ECL label molecules and detection reagents labeled with the ECL label molecules for bioanalytical assays, es...
|
|
WO/2021/085528A1 |
Provided is a CD4 mimic compound which has more improved in vivo kinetics and improved efficacy in anti-HIV treatment. Provided are: a compound represented by formula (I) [in the formula, R1 represents -C2H4(OC2H4)n-OCH3 or CmH2m+1, R2...
|
|
WO/2021/084217A1 |
The present invention provides processes for the preparation of a hydrochloric acid salt of compound of formula (2): (I) Compound of formula (2) wherein: R1 is selected from the group consisting of -H, an unsubstiuted straight-chain C1-C...
|
|
WO/2021/066435A1 |
The present invention relates to a compound for an organic electric element, an organic electric element using same, and an electronic device comprising the organic electric element. According to the present invention, an organic electri...
|
|
WO/2021/057882A1 |
A compound of formula I, a method for using these compounds as an EGFR inhibitor, and a pharmaceutical composition comprising these compounds. The compound is used in the treatment, prevention or amelioration of diseases or conditions su...
|
|
WO/2021/057832A1 |
Privided is a KRAS mutant protein inhibitor, a composition containing the inhibitor and the use thereof.
|
|
WO/2021/059017A1 |
Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine...
|
